(Q44878422)

English

High incidence of renal stones among HIV-infected patients on ritonavir-boosted atazanavir than in those receiving other protease inhibitor-containing antiretroviral therapy

scientific article published on 19 July 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

High incidence of renal stones among HIV-infected patients on ritonavir-boosted atazanavir than in those receiving other protease inhibitor-containing antiretroviral therapy (English)

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

9

object named as

Shinichi Oka

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

author name string

Yohei Hamada

1

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Takeshi Nishijima

2

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Koji Watanabe

3

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Hirokazu Komatsu

4

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Kunihisa Tsukada

5

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Katsuji Teruya

6

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Hiroyuki Gatanaga

7

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Yoshimi Kikuchi

8

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

language of work or name

0 references

publication date

19 July 2012

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Clinical Infectious Diseases

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

55

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

9

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

1262-1269

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS621

21 January 2018

Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE st

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS621

21 January 2018

Atazanavir urolithiasis

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS621

21 January 2018

The etiology of urolithiasis in HIV infected patients

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS621

21 January 2018

Kidney stones and the risk for chronic kidney disease

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS621

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS621

21 January 2018

Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS621

21 January 2018

Ritonavir-boosted atazanavir exposure is associated with an increased rate of renal stones compared with efavirenz, ritonavir-boosted lopinavir and ritonavir-boosted darunavir

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS621

21 January 2018

Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS621

21 January 2018

A randomized, pilot trial to evaluate glomerular filtration rate by creatinine or cystatin C in naive HIV-infected patients after tenofovir/emtricitabine in combination with atazanavir/ritonavir or efavirenz

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS621

21 January 2018

Renal function in patients with HIV starting therapy with tenofovir and either efavirenz, lopinavir or atazanavir

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS621

21 January 2018

Lopinavir-ritonavir (Kaletra) and lithiasis: seven cases

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS621

21 January 2018

Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C-->T polymorphism at the multidrug resistance gene 1

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS621

21 January 2018

Identifiers

10.1093/CID/CIS621

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44878422&oldid=2055054720"